2.35
+0.06(+2.62%)
Currency In USD
| Previous Close | 2.29 |
| Open | 2.3 |
| Day High | 2.35 |
| Day Low | 2.26 |
| 52-Week High | 10.54 |
| 52-Week Low | 1.11 |
| Volume | 265,793 |
| Average Volume | 324,554 |
| Market Cap | 45.79M |
| PE | -1.12 |
| EPS | -2.1 |
| Moving Average 50 Days | 2.56 |
| Moving Average 200 Days | 3.02 |
| Change | 0.06 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $245.05 as of September 09, 2025 at a share price of $2.35. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $153.59 as of September 09, 2025 at a share price of $2.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Completes Full Patent Transfer to Crystal Buntanetap
GlobeNewswire Inc.
Aug 07, 2025 12:00 PM GMT
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed international
Annovis to Attend the AAIC 2025 with Four Poster Presentations
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease